• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Pathophysiology and treatment of congestive heart failure--recently advanced strategy for heart failure].

作者信息

Kitabatake A

机构信息

Department of Cardiovascular Medicine, Hokkaido University School of Medicine, Sapporo, Japan.

出版信息

Hokkaido Igaku Zasshi. 1995 Jan;70(1):9-18.

PMID:7744373
Abstract

The principle functions of the heart are to accept blood from the systemic and the pulmonary circulatory system, pump and deliver it to the whole body tissues and lungs. The term "heart failure" is used to describe the pathophysiological state in which an abnormality of cardiac function is responsible for failure of the heart to pump blood at a rate commensurate with the requirements of the metabolizing tissues, or to do so only from an elevated filling pressure. Thus, for a long period, heart failure has been thought of as a mechanical disorder of the heart and vessels, and its treatment has been based on improving impaired cardiac function and hemodynamic disorder. Recently multi-center, randomized placebo-controlled survival trials revealed that pure inotropic agents such as phosphodiesterase inhibitors succeeded in mechanical improvement, yet not only failed to prolong the patient's life, but also increased mortality. A number of neurohumoral mechanisms, which are activated in heart failure, were thought to be compensatory ones. However, survival trials demonstrated that two types of drug interfering with the renin-angiotensin system and the sympathetic nervous system reduced mortality. Those drugs are angiotensin-converting enzyme (ACE) inhibitors and beta blockers. ACE inhibitors reduce the direct effects of angiotensin II on myocardial cells, which may lead to cell necrosis, imbalanced remodeling through fibrosis, and attenuate the progressive ventricular dilatation. Local tissue renin-angiotensin system may be potentially important in regulating the angiotensin II production in both heart and vessels.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
[Pathophysiology and treatment of congestive heart failure--recently advanced strategy for heart failure].
Hokkaido Igaku Zasshi. 1995 Jan;70(1):9-18.
2
Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.血管紧张素II受体拮抗剂与心力衰竭:血管紧张素转换酶抑制剂仍是一线选择。
Prescrire Int. 2005 Oct;14(79):180-6.
3
The renin-angiotensin system in the heart and vascular wall: new therapeutic aspects.心脏和血管壁中的肾素-血管紧张素系统:新的治疗方面。
J Cardiovasc Pharmacol. 1994;24 Suppl 2:S6-13.
4
Mechanistic and clinical rationales for using beta-blockers in heart failure.在心力衰竭中使用β受体阻滞剂的机制及临床依据。
J Card Fail. 2000 Jun;6(2 Suppl 1):8-14.
5
The cellular and physiologic effects of beta blockers in heart failure.β受体阻滞剂在心力衰竭中的细胞和生理效应。
Clin Cardiol. 1999 Oct;22 Suppl 5:V16-20.
6
Changes in beta-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system.心肌梗死所致心力衰竭时β-肾上腺素能受体的变化可因肾素-血管紧张素系统的阻断而减弱。
Mol Cell Biochem. 2004 Aug;263(1-2):11-20.
7
[How and to what extent has beta-blocker treatment been established for chronic heart failure?].[β受体阻滞剂治疗慢性心力衰竭的方法及确立程度如何?]
J Cardiol. 1996 Aug;28(2):99-112.
8
[New knowledge on the subject of therapy in cardiac decompensation in the light of large trials].基于大型试验的心力衰竭治疗主题新知识
Ann Ital Med Int. 1994 Oct;9 Suppl:68S-77S.
9
[New therapeutic prospects in heart failure. ACE inhibitors and beta blockers].[心力衰竭的新治疗前景。血管紧张素转换酶抑制剂和β受体阻滞剂]
Recenti Prog Med. 1999 Mar;90(3):136-42.
10
Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.血管紧张素转换酶抑制剂和血管紧张素II受体拮抗剂在治疗左心室收缩功能障碍引起的心力衰竭中的应用。
Prog Cardiovasc Dis. 1999 Jan-Feb;41(4):265-300. doi: 10.1053/pcad.1999.0410265.